Biochemistry
Investigators at Vanderbilt University Medical Center have published new research on the impact of the tumor-specific EphA2 receptor tyrosine kinase on non-small cell lung cancer (NSCLC). According to the report, EphA2 plays a crucial role in tumor growth and metastasis and has been identified as a viable target for many
Biochemistry
A recent study on non-small cell lung cancer (NSCLC) has shown promising results for a treatment regimen that combines neoadjuvant chemo-immunotherapy with antiangiogenic drugs. The study, conducted by researchers from the Department of Thoracic Surgery, found that this combination significantly improved long-term survival outcomes in patients with resectable NSCLC. Key
Biochemistry
Researchers from M.S. Ramaiah University of Applied Sciences have discovered a novel approach to overcoming resistance to osimertinib, a third-generation epidermal growth factor receptor inhibitor, in non-small cell lung cancer (NSCLC). By combining osimertinib with epigallocatechin-3-gallate (EGCG), a green tea polyphenol, they found that the combination therapy significantly enhanced
Biochemistry
New research out of Universita Cattolica del Sacro Cuore in Rome, Italy, has found that circulating tumor DNA (ctDNA) may hold the key to more accurate and innovative detection and treatment of early-stage non-small cell lung cancer (NSCLC). The study, published in the journal Genes, highlights the potential of ctDNA
Cancer research
Researchers at the National Clinical Research Center for Cancer have made significant strides in personalized medicine for lung adenocarcinoma, the most common subtype of non-small cell lung cancer. By analyzing transcriptomic and single-cell RNA sequencing data, the team identified an ac4C-related gene signature (ARGSig) that can predict survival outcomes and
Cancer research
Personalis, Inc., a leader in advanced genomics for precision oncology, has announced new data from an AstraZeneca phase 3 clinical trial in lung cancer, demonstrating that its highly sensitive molecular residual disease (MRD) test, NeXT Personal, is a strong predictor of outcomes in patients with stage II-IIIb, EGFR-mutated non-small cell
Cancer research
Researchers from Kunming Medical University in China have published a review of the effects of anti-angiogenic therapy combined with immunotherapy and radiotherapy for the treatment of brain metastases in non-small cell lung cancer (NSCLC). The study aimed to provide ideas for the treatment of NSCLC with brain metastases. The authors
Cancer research
Researchers from the Third People's Hospital of Zhengzhou, Henan, China, have made a significant discovery in the treatment of non-small cell lung cancer (NSCLC). The study, recently published in Scientific Reports, reveals that combining neoadjuvant immunotherapy with chemotherapy can improve resection rates, survival, and progression-free survival in patients
Cancer research
Research on non-small cell lung cancer (NSCLC) has shown that microwave ablation (MWA) is an effective treatment option for elderly patients with stage I NSCLC. According to a recent study published in Cancer Imaging, the efficacy of MWA for patients aged 75 years with stage I NSCLC was evaluated, and
Immunotherapy
Researchers at the Curie Institute in Paris, France have conducted a retrospective analysis of a large database of lung cancer patients to investigate the impact of KRAS mutations on disease phenotype and survival outcomes. The study found that patients with KRAS mutations were more likely to be smokers and had
Non-small cell lung cancer
Dr. Simon E. Beltran, a respected emergency room physician and devoted husband, father, and grandfather, passed away peacefully on August 20, 2024, after a courageous four-month battle with non-small cell lung cancer. Born on May 11, 1948, in the Panama Canal Zone, Dr. Beltran spent his life serving others, from
